Morphosys: Das sind die Ziele von CEO Kress & Co - DER AKTIONÄR
Ad hoc: MorphoSys Appoints Jean-Paul Kress, M.D., as New Chief Executive Officer | Morphosys de
Jean-Paul Kress - CEO - MorphoSys | LinkedIn
Samsung, Biogen version of AbbVie's Humira approved in Europe | Reuters
New CEO at Morphosys - European Biotechnology
Abarca Announces Innovative Value-Based Contract with Biogen
Jean-Paul Kress M.D. — Executive VP, President of International, Head of Global Therapeutic Operations at Biogen | Comparably
Jean-Paul Kress, M.D. | Morphosys de
Jean-Paul Kress - CEO - MorphoSys | LinkedIn
Jean-Paul Kress | Les Amateurs Virtuoses
Chutes & Ladders—Biogen executive Kress takes over the reins of Syntimmune | Fierce Biotech
MorphoSys acquires Constellation Pharma for $1.7B - Boston Business Journal
Jean-Paul Kress Net Worth (2023) | wallmine
Abarca Health, Biogen ally on multiple sclerosis coverage – News is My Business
The Top 25 Healthcare Technology Leaders of Massachusetts for 2023 | The Healthcare Technology Report.
Jean-Paul Kress email address & phone number | Morphosys Chairman of the Board of Management, Chief Executive Officer contact information - RocketReach
What Biogen CFO's Departure Means for Company's M&A Strategy | BioSpace
Imraldi, Biogen's Humira Biosimilar, Gains EC Approval - Drug Discovery and Development
Jean-Paul Kress email address & phone number | Morphosys Chairman of the Board of Management, Chief Executive Officer contact information - RocketReach
Dr. Jean-Paul Kress is new CEO of MorphoSys AG - Innovations- und Gründerzentrum Biotechnologie IZB
Jean-Paul Kress - Biography
Morphosys: Missmanagement bei Deutschlands einstigem Biotechstar - manager magazin
Jean-Paul Kress - CEO at MorphoSys | The Org
